Skip to main content

Integrating chemical approaches to treat pancreatic cancer: making new leads for a cure

Objetivo

Pancreatic ductal adenocarcinoma (PDAC) causes 34000 deaths in the EU every year. Conventional cancer treatments have close to no impact on this disease. As a result, almost all patients diagnosed with PDAC develop metastases and eventually die. Given this poor outlook, the search for new therapeutics is mandatory. These will have to target relevant cancer pathways and be designed based on the available knowledge on the genetic alterations that characterize this malignancy. We propose to build a team composed of clinicians, translational cancer researchers, chemists, and two pharmaceutical enterprises, to synthesize and implement new drugs for PDAC. The focus of the participants in this project will be on pathways and cellular functions broadly involved in PDAC metastasis and immune escape. These drugs are meant to work through diverse and novel modes of action and will be validated using genetically engineered PDAC mouse models that we have established at the Center for Integrated Oncology in Bonn. By creating and exploring diverse classes of compounds capable of arresting tumor growth and of interfering with its metastatic spread, this project will deliver a high number of new molecules with potential as anticancer therapeutics. In particular, our consortium will produce new indoleamine 2,3-dioxygenase-2 (IDO2) inhibitors, galectin-3 inhibitors, edelfosine analogues, inhibitors of the Hippo signaling pathway, alpha-mannosidase inhibitors, SIRT6 inhibitors, and therapeutics acting by synthetic lethality. For compounds with strong proof-of-concept activity, our consortium will perform the Investigational New Drug (IND)-Enabling Studies, with the goal of delivering a new drug ready to be tested clinically by the end of the project. The PANACREAS project is meant to help find better treatments for PDAC, boost research on this form of cancer in the EU, and open new avenues for scientific and technological innovation.

Convocatoria de propuestas

FP7-HEALTH-2010-two-stage
Consulte otros proyectos de esta convocatoria

Coordinador

UNIVERSITATSKLINIKUM BONN
Dirección
Venusberg-campus 1
53127 Bonn
Alemania

Ver en el mapa

Tipo de actividad
Higher or Secondary Education Establishments
Contacto administrativo
Beate Becker (Ms.)
Aportación de la UE
€ 457 200

Participantes (11)

UNIVERSITA DEGLI STUDI DI GENOVA
Italia
Aportación de la UE
€ 359 016,53
Dirección
Via Balbi 5
16126 Genova

Ver en el mapa

Tipo de actividad
Higher or Secondary Education Establishments
Contacto administrativo
Maria Angela Ferrera (Ms.)
AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS
España
Aportación de la UE
€ 276 237,50
Dirección
Calle Serrano 117
28006 Madrid

Ver en el mapa

Tipo de actividad
Research Organisations
Contacto administrativo
Eusebio Jiménez Arroyo (Mr.)
ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE
Suiza
Aportación de la UE
€ 429 600
Dirección
Batiment Ce 3316 Station 1
1015 Lausanne

Ver en el mapa

Tipo de actividad
Higher or Secondary Education Establishments
Contacto administrativo
Paul Dyson (Prof.)
CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS
Suiza
Aportación de la UE
€ 269 280
Dirección
Rue Du Bugnon 21
1011 Lausanne

Ver en el mapa

Tipo de actividad
Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
Contacto administrativo
François Mermoud (Mr.)
UNIVERSIDAD DE SEVILLA
España
Aportación de la UE
€ 189 280
Dirección
Calle S. Fernando 4
41004 Sevilla

Ver en el mapa

Tipo de actividad
Higher or Secondary Education Establishments
Contacto administrativo
Margarita Martínez-Pais Loscertales (Ms.)
UNIVERSITA DEGLI STUDI DI TRENTO
Italia
Aportación de la UE
€ 172 089
Dirección
Via Calepina 14
38122 Trento

Ver en el mapa

Tipo de actividad
Higher or Secondary Education Establishments
Contacto administrativo
Alessandro Provenzani (Dr.)
MAX IV Laboratory, Lund University
Suecia
Aportación de la UE
€ 280 720
Dirección
Paradisgatan 5c
22100 Lund

Ver en el mapa

Tipo de actividad
Higher or Secondary Education Establishments
Contacto administrativo
Ulf Nilsson (Prof.)
DEBIOPHARM S.A.

La participación finalizó

Suiza
Aportación de la UE
€ 47 883,47
Dirección
"Chemin Messidor - Forum ""Apres-demain"" 5-7"
1002 Lausanne
Tipo de actividad
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Contacto administrativo
Oengus Ramsay (Mr.)
APOINTECH SL
España
Aportación de la UE
€ 202 150
Dirección
Calle Rio Duero 12
37185 Villamayor De La Armuna

Ver en el mapa

Tipo de actividad
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Contacto administrativo
Pablo Escriba Ruiz (Dr.)
ALTA RICERCA E SVILUPPO IN BIOTECNOLOGIE SRLU
Italia
Aportación de la UE
€ 89 600,50
Dirección
Via Fiorentina 151
53100 Siena

Ver en el mapa

Tipo de actividad
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Contacto administrativo
Cristiana Tozzi (Dr.)
SIB SWISS INSTITUTE OF BIOINFORMATICS
Suiza
Aportación de la UE
€ 192 150
Dirección
Rue Michel Servet 1 Cmu
1206 Geneve

Ver en el mapa

Tipo de actividad
Research Organisations
Contacto administrativo
Jocelyne Bocquet (Ms.)